Ananda Ventures invests in maternal health diagnostics company Aitiologic

Ananda Ventures invested in Aitiologic, which uses routine prenatal blood samples to screen for maternal health complications. Aitiologic's Aitios test outperformed standard screening for preterm and term preeclampsia in a Fetal Medicine Foundation study published as a preprint. A 1,000-sample blinded validation is scheduled to report interim results at the end of 2026. Gestational diabetes is already included in the validation study, broadening the platform's potential beyond preeclampsia. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ananda Ventures GmbH published the original content used to generate this news brief on October 16, 2026, and is solely responsible for the information contained therein. (C)